Condition: Relapsing Multiple Sclerosis · Sponsor: Novartis Pharmaceuticals
This non-interventional study will compare the effect of Ofatumumab treatment between patients that began Ofatumumab within the 3 years after Multiple Sclerosis diagnosis and patients that began Ofatumumab with more than 3 years of Multiple Sclerosis diagnosis in a real-world setting in Portugal.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Amadora, Portugal | Recruiting |
| Novartis Investigative Site | Guimarães, Portugal | Recruiting |
| Novartis Investigative Site | Leiria, Portugal | Recruiting |
| Novartis Investigative Site | Lisbon, Portugal | Recruiting |
| Novartis Investigative Site | Lisbon, Portugal | Recruiting |
| Novartis Investigative Site | Lisbon, Portugal | Recruiting |
| Novartis Investigative Site | Matosinhos Municipality, Portugal | Recruiting |
| Novartis Investigative Site | Ponte de Lima, Portugal | Recruiting |
| Novartis Investigative Site | Porto, Portugal | Recruiting |
| Novartis Investigative Site | Setúbal, Portugal | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05809986